TipRanks
DuPont de Nemours (DD)
NYSE:DD
US Market
Want to see DD full AI Analyst Report?
EarningsQ2 2026 Earnings Report

DuPont de Nemours (DD) Q2 2026 Earnings Report

4,294 Followers

DD Q2 2026 EPS Results

Actual EPS$1.88
Consensus EPS$1.76
Beat/MissBeat by +$0.12
One Year Ago EPS$1.41

DD Q2 2026 Revenue Results

Actual Revenue$1.82B
Expected Revenue$1.81B
Beat/MissBeat by +$12.53M
YoY Revenue Growth-44.15%

Earnings Announcement Details

QuarterQ2 2026
Date08/04/2026
TimeBefore Open
Conference CallTuesday, August 4, 2026
DD Upcoming Earnings
DuPont de Nemours's next earnings date is estimated for November 3, 2026, based on past reporting schedules.

Q2 2026 Earnings Call Audio

DD Q2 2026 Earnings Call
0:00 / 0:00

Q2 2026 Earnings Slide Deck

Q2 2026 Earnings Call Summary

Q2 2026
Earnings Call Date:Aug 04, 2026|
% Change Since:
|
Earnings Call Sentiment|Positive
The call was broadly positive: DuPont reported a quarter that beat guidance across key metrics (sales, EBITDA, EPS), delivered strong free cash flow (127% conversion), raised full-year guidance, announced a $250M buyback and showcased operational improvements (productivity, OTIF, lower cost of poor quality) and promising commercial/innovation momentum (AI-enabled sales plays, DLE launch, EV battery ramp). Offsetting items include near-term timing and project headwinds in the Middle East impacting Water, margin pressure in Healthcare & Water from mix and investments, oil & gas inflationary headwinds (partially mitigated by $90M of pricing), and modest currency headwinds. Overall the positives — improved organic growth, margin expansion, cash generation, capital allocation actions, and scaling commercial and operational programs — outweigh the localized and addressable headwinds.
Company Guidance
DuPont raised full‑year 2026 guidance after a strong Q2 beat (Q2 net sales $1.8B, +4% organic; operating EBITDA $448M, +8%; EBITDA margin 24.6%, +80 bps; adj. EPS $1.88, +21%; transaction‑adjusted FCF $326M, 127% conversion). The company now expects full‑year net sales midpoint $7.175B with organic growth slightly ahead of 4%, operating EBITDA midpoint $1.760B and operating EBITDA margin ~24.5% (including a ~30 bps oil & gas inflation headwind), adj. EPS midpoint $7.24 (≈+18% vs PY pro forma), and free cash flow conversion expected ahead of the 90% target (closer to 100%). For H2 the company estimates net sales $3.675B with ~6% organic growth, operating EBITDA $900M (margin ~24.5% including a ~50 bps oil & gas headwind) and H2 adj. EPS midpoint $3.73; Q3 guidance is net sales $1.835B, operating EBITDA $448M, margin ~24.4% (50 bps headwind), adj. EPS $1.80–$1.90, and ~5% organic growth (adjusted for prior‑year timing), while capital allocation includes a $250M share repurchase announced for Q3.
Beat Guidance and Raised Full-Year Outlook
Q2 performance exceeded prior guidance and management raised full-year 2026 targets: organic sales growth now expected slightly ahead of 4%, operating EBITDA midpoint increased to $1.760 billion, and adjusted EPS midpoint raised to $7.24 (approximately +18% vs prior year pro forma and +$0.15 vs prior guide).
Strong Quarterly Financial Results
Net sales of $1.8 billion (up 4% year-over-year on 4% organic growth); operating EBITDA of $448 million (up 8% YoY) and operating EBITDA margin of 24.6% (up 80 basis points YoY); adjusted EPS of $1.88 (up 21% YoY).
Robust Cash Flow and Capital Deployment
Transaction-adjusted free cash flow of $326 million with conversion of 127%; management expects full-year free cash flow conversion to be ahead of the 90% target and CFO said closer to 100% on a full-year basis. Announced a $250 million share repurchase program launching in Q3 and retained >$1 billion of capacity for M&A.
Operational Productivity and Quality Gains
Delivered ~200 basis points COGS reduction this quarter (contributing ~100 basis points of margin expansion); set a net productivity target of 3% of COGS (goal within ~18 months); OTIF and net productivity improved by more than 100 basis points; cost of poor quality ~4% of sales (below ~5% benchmark).
Innovation Pipeline and Commercial Execution
Innovation vitality index ~35%; launched AI-enabled commercial initiatives with ~50 sales plays and ~150 opportunities (nearly 30% win rate in targeted garment plays), shortening sales-play deployment to ~4 weeks and generating ~$5–6 million incremental garment sales.
Diversified Industrials Momentum
Diversified Industrials net sales $963 million (up 3% YoY organic); operating EBITDA $213 million (up 7% YoY) and margin expanded to 22.1% (up 70 basis points YoY). Building Technologies and Industrial Technologies showed growth, with aerospace and EV battery applications driving mid-single-digit gains in Industrial Technologies.
Healthcare & Water Growth and New Solutions
Healthcare & Water net sales $856 million (up 5% YoY — 4% organic + 1% currency). Healthcare delivered mid-single-digit organic growth, driven by personal protection and biopharma; launched integrated DLE (direct lithium extraction) solution and expanded the Liveo biopharma portfolio.
Battery & Semiconductor Opportunity Capture
EV battery-related revenue ~ $70 million today with management expecting it to reach triple digits in 2026–2027; broader EV opportunity is a few hundred million. Water ultra-pure solutions for semiconductor customers have been growing strongly (>20%+ in recent quarters).

DD Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Nov 03, 2026
2026 (Q3)
1.87 / -
3.27―
2026 (Q2)
1.76 / 1.88
1.40533.81% (+0.47)
2026 (Q1)
1.46 / 1.65
1.29227.71% (+0.36)
2025 (Q4)
1.29 / 1.38
1.418-2.68% (-0.04)
2025 (Q3)
1.40 / 3.27
1.481120.80% (+1.79)
2025 (Q2)
1.33 / 1.41
1.21715.45% (+0.19)
2025 (Q1)
1.20 / 1.29
0.99130.37% (+0.30)
2024 (Q4)
1.23 / 1.42
1.09229.85% (+0.33)
2024 (Q3)
1.29 / 1.48
1.15428.34% (+0.33)
2024 (Q2)
1.07 / 1.22
1.06714.06% (+0.15)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed